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APPs also appears to mediate the neurite outgrowthDepartment of Neurology
response to nerve growth factor (NGF) in PC12 cells,Harvard Medical School
raising the possibility that altered processing of APPand Division of Neuroscience
could affect neuronal reponsiveness to neurotrophicThe Children's Hospital
factors (Milward et al., 1992). Several effects of APP onBoston, Massachusetts 02115
cell signaling have been described. APP can associate
with heterotrimeric G proteins (Nishimoto et al., 1993),Alzheimer's disease (AD) is the most common cause of
and APPs can activate high conductance potassiumprogressive cognitive decline in the aged population.
channels (Furukawa et al., 1996) and increase the activ-The triad of amyloid plaques, neurofibrillary tangles, and
ity of MAP kinase (Greenberg et al., 1994). However, thedementia that characterize AD was first described by
relevance of these effects to the biological functions ofAlois Alzheimer in 1907. Despite considerable progress
APP has not been established.in elucidating the molecular components of the brain
The biological functions of APP in vivo have recentlylesions, the mechanism of neuronal degeneration in AD
been examined in homozygous APP-knockout mice.has been unclear. However, recent advances in molecu-
APP-knockout mice proceed through gestation nor-lar genetics have focused attention on several patho-
mally, suggesting that APP is not absolutely requiredgenic mechanisms. There are now four different genes
during development (Zheng et al., 1995). As adults, theythat confer susceptibility to ADÐthe amyloid precursor
exhibit a 15%±20% decrease in weight, decreased loco-protein (APP), apolipoprotein E (ApoE), and two novel
motor activity, and forelimb motor abnormalities. Theseven transmembrane domain proteins. Although it is
only detectable abnormality in the brain is diffuse reac-likely that multiple molecular pathways can lead to AD,
tive gliosis without clear evidence of neuronal degenera-
a central issue is whether all causes of the disease lead
tion. The minimal cortical pathology in the complete
to a final common mechanism of neuronal death. This
absence of APP is somewhat surprising in light of the
review describes recent advances in the molecular ge- known effects of APPs on neurons in vitro, raising thenetics and cell biology of AD and discusses the potential possibility that the APP deficit may have been partially
pathogenic mechanisms that emerge. compensated. Another mouse model has been devel-
oped in which a mutant form of APP lacking exon 2 is
expressed. These animals exhibit cognitive impairmentThe Amyloid Precursor Protein
and agenesis of the corpus callosum (MuÈ ller et al., 1994).Genetic and cell biological studies have implicated APP
However, the absence of these changes in homozygousin the pathogenesis of AD. APP is a transmembrane
APP-deficient mice suggests that the mutant APP mayglycoprotein that is the precursor of amyloid b (Ab), a
have given rise to a new dominant phenotype.40±42 amino acid peptide that is the principal constit-
Two other mammalian proteins that are highly homol-uent of senile plaques and cerebrovascular deposits in
ogous to APP, APLP1 and APLP2, have been cloned,AD (Figure 1) (Glenner and Wong, 1984; Masters et al.,
suggesting that APP is a member of a multigene family1985; Kang et al., 1987). Three major isoforms of APP
(Wasco et al., 1992, 1993; Slunt et al., 1994). APLP2 isareproduced by alternative splicing. Isoforms of 751 and
present in postsynaptic compartments throughout the770 amino acids contain an N-terminal Kunitz protease
cortex and is enriched in axon terminals of olfactoryinhibitor domain and are expressed in both neural and
sensory neurons, consistent with a potential role in axo-non-neural tissues (Kitaguchi et al., 1988; Ponte et al.,
nal growth or synaptogenesis (Thinakaran et al., 1995).1988; Tanzi et al., 1988). A 695 amino acid isoform is
APP homologs have also been identified in Drosophila
expressed at high levels in neurons, where it undergoes
and Caenorhabditis elegans (Luo et al., 1992; Daigle and
anterograde and retrograde axonal transport and trans-
Li, 1993). Interestingly, deletion of the Drosophila gene
cytosis (Koo et al., 1990; Yamazaki et al., 1995). APP is
results in subtle behavioral deficits that are rescued by
normally cleaved within the Ab domain to generate a either the Drosophila or human genes, suggesting that
90±100 kDa secreted form (Weidemann et al., 1989; Esch there is phylogenetic conservation of function among
et al., 1990; Sisodia et al., 1990). An alternative pro- APP homologs.
cessing pathway in which APP is cleaved at different An important question is whether loss of APP function
sites in the extracellular and transmembrane domains contributes to the pathogenesis of AD. Cerebrospinal
generates soluble Ab, the putative source of plaque fluid levels of APPs have been demonstrated to be signif-
amyloid in AD (Haass et al., 1992; Shoji et al., 1992; icantly decreased in AD (Van Nostrand et al., 1992). APPs
Seubert et al., 1992; Busciglio et al., 1993a). The regula- can protect cultured neurons from a variety of stresses,
tion of APP processing and secretory trafficking has including glucose deprivation, EAA toxicity, and oxida-
been reviewed elsewhere (Selkoe, 1994). tion, by a mechanism that may involve stabilization of
The physiological role of APP in the brain is not well intracellular calcium (Mattson et al., 1993a; Schubert
understood. The secreted form of APP (APPs) can func- and Behl, 1993). Furthermore, overexpression of APP in
tion as an autocrine factor to stimulate cell proliferation transgenic mice can increase the number of cortical
(Saitoh et al., 1989) and can promote cell±substratum synapses and protect against the neurotoxicity of the
adhesion, possibly through an interaction with laminin HIV gp120 protein (Mucke et al., 1994, 1995). Thus, de-
creased levels of APPs in AD could potentially render(Schubert et al., 1989; Chen and Yankner, 1991; Breen
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within Ab that accelerates the rate of Ab fibril formation
in vitro (Levy et al., 1990; Wisniewski et al., 1991). Thus,
the effects of inherited APP mutations provide support
for the idea that increased Ab generation or aggregation
may lead to the development of AD.
The demonstration that Ab and APP C-terminal frag-
ments containing Ab are neurotoxic in cell culture gave
rise to the hypothesis that Ab may be a primary cause
of neuronal degeneration in AD (Yankner et al., 1989,
1990a, 1990b; Pike et al., 1991; Roher et al., 1991). The
neurotoxicity of Ab is dependent on its aggregation state
(Pike et al., 1991, 1993; Busciglio et al., 1992; Mattson
et al., 1993b). Recent studies demonstrate that Ab neu-
rotoxicity requires the assembly of Ab into amyloid fi-
brils, whereas nonfibrillar, amorphous aggregates of Ab
are not neurotoxic (Lorenzo and Yankner, 1994; Buscig-
lio et al., 1995; Howlett et al., 1995). This observation is
consistent with pathological studies of the AD brain
which show that neurodegenerative changes occur
around compact plaques composed of Ab fibrils, but
not around diffuse plaques composed of amorphous Ab
aggregates (Mann and Esiri, 1989; Yamazaki et al., 1992).
Amyloid fibrils form from proteins and peptides that can
adopt a crossed b-sheet conformation under pathologi-
cal conditions. Amyloid plaque formation may involve
two basic stepsÐthe initial formation of a seeding ag-
Figure 1. Inherited Mutations That Cause AD gregate (Jarrett and Lansbury, 1993) followed by long-
(A) APP. Sites of inherited mutations surrounding or within the Ab term deposition of the peptide (Maggio et al., 1992).
domain are shown with asterisks. The mutations either increase Ab Increasing evidence suggests that this process may be
production, alter the length of Ab, or increase Ab aggregation. initiated by increased production of the highly aggre-
(B) The seven transmembrane domain protein S182. Shown are
gable 42 amino acid form of Ab (Barrow and Zagorski,the sites of five inherited mutations in S182 and a mutation in the
1991; Iwatsubo et al., 1994; Suzuki et al., 1994). Assem-homologous protein STM2. Five of the six mutations are proximal
bly of Ab into fibrils may also be catalyzed by severalto a transmembrane domain.
factors that bind to Ab and increase its aggregation in
vitro, including ApoE (see below), heparin sulfate proteo-neurons more vulnerable to neurotoxic insults. It will
glycan (Fraser et al., 1992; Snow et al., 1994), and the
therefore be important to determine whether the altered
heavy metals zinc and aluminum (Mantyh et al., 1993;
processing of APP that gives rise to amyloid deposition
Bush et al., 1994; Fasman et al., 1995). In addition, oxida-
also decreases the production of APPs, resulting in in- tion of Ab can promote aggregation by peptide cross-
creased neuronal vulnerability.
linking (Dyrks et al., 1992), a potentially important factor
in light of increasing evidence for the involvement of
Role of Ab Protein oxidative stress in AD (see below).
The hypothesis that APP or Ab play a role in the patho- Ab neurotoxicity may reflect a more general neurode-
genesis of AD is supported by three lines of evidenceÐ generative mechanism, since other amyloidogenic pep-
the association of AD with inherited APP mutations, the tides are also toxic to neurons in vitro, including amylin,
association of AD with APP overexpression in Down's serum amyloid P component, and a peptide derived
syndrome, and the neurotoxicity of Ab fibrils. Inherited from the prion protein (Forloni et al., 1993a; May et al.,
APP mutations are rare, but potentially shed light on 1993; Lorenzo et al., 1994; UrbaÂnyi et al., 1994). These
important pathogenic mechanisms. All of the inherited peptides cause apoptosis of their target cells (Forloni
APP mutations identified in families with autosomal et al., 1993b; Loo et al., 1993; Lorenzo et al., 1994). A
dominant inheritance of AD occur in proximity to the Ab general requirement for fibril formation was suggested
domain (Figure 1). The first mutation was identified at by the observation that the diabetes-associated peptide
APP codon 717, proximal to the APP cleavage site that amylin is toxic to pancreatic islet cells only when it forms
generates the Ab C-terminus (Goate et al., 1991). Ex- amyloid fibrils (Lorenzo et al., 1994). Thus, amyloid fibrils
pression of this mutant APP in cultured cells results in are cytotoxic to cell types other than neurons, raising
increased production of the highly aggregable 42 amino the possibility that fibril formation may contribute not
acid form of Ab (Suzuki et al., 1994), the predominant only to AD, but also to the pathogenesis of systemic
form of Ab in senile plaques (Roher et al., 1993). A sec- amyloid-related diseases. Inhibition of amyloid fibril for-
ond inherited APP mutation alters the two amino acids mation may therefore be a potential therapeutic ap-
adjacent to the Ab N-terminus (Mullan et al., 1992), re- proach. The feasibility of this approach has been dem-
sulting in a severalfold increase in Ab production (Citron onstrated in vitro using the amyloid-binding dye Congo
et al., 1992; Cai et al., 1993). Dutch families with an red and related organic compounds. These agents in-
inherited hemmorhagic disorder characterized by Ab hibit fibril formation from several different amyloido-
genic peptides as well as the toxicity of Ab and amylindeposition in the cerebral bloodvessels carry a mutation
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Figure 2. Ab Fibril Formation and Potential
Mechanisms of Neurotoxicity
Age-related factors or inherited mutations in-
duce the formation of Ab fibrils, which may
cause neuronal degeneration through several
potential cellular mechanisms.
(Lorenzo and Yankner, 1994; Kisilevsky et al., 1995; Pol- conditions, they suggest that effects on calcium influx
and free radical generation may not explain the entirelack et al., 1995; Podlisny et al., 1995). Congo red also
inhibits accumulation of thepathogenic form of theprion spectrum of b-amyloid neurotoxicity.
The general cytopathic effect of amyloid fibrils sug-protein in infected cells in culture (Caughey and Race,
1992), raising the possibility that similar conformational gests that the structure of the fibril, rather than the se-
quence of its constituent peptide, is responsible for tox-changes may underlie the formation of pathogenic forms
of Ab and prion. icity. One possible model is that amyloid fibrils interact
with cell surface receptors that recognize b-sheet struc-Elucidation of the molecular mechanism of Ab neuro-
toxicity has been confounded by the many effects of ture in their endogenous ligands, resulting in aberrant
activation of signal transduction pathways (Figure 2).Ab on cells in culture (Figure 2). In addition to its direct
neurotoxic effect, Ab can potentiate the toxic effects of This mechanism is consistent with observed increases
in the phosphorylation of focal adhesion kinase (Zhanga variety of different neuronal insults including excitatory
amino acids (EAAs) (Koh et al., 1990; Mattson et al., et al., 1994) and the microtubule-associated protein tau
(Busciglio et al., 1995). Neuronal apoptosis may be a1992), glucose deprivation (Copani et al., 1991), and
oxidative stress (Lockhart et al., 1994). However, the consequence of persistant binding and activation of cell
surface receptors by amyloid fibrils, analogous to thedirect neurotoxicity of Ab is not mediated by EAAs (Bus-
ciglio et al., 1993b, Pike et al., 1993). Addition of Ab induction of apoptosis by interaction of the FAS ligand
with its cell surface receptor. An alternative possibilityand other amyloidogenic peptides to primary neurons
results in a slow increase in intracellular calcium, an is that Ab may act by forming a membrane pore, leading
to increased ion influx. This phenomenon has been ob-effect that has been proposed to mediate neurotoxicity
(Mattson et al., 1992; Mattson and Goodman, 1995). served in artificial lipid membranes, but has not been
demonstrated in intact cells (Arispe et al., 1993). It re-However, other laboratories have reported that calcium
channel blockers and calcium chelating agents do not mains to be determined whether Ab neurotoxicity is
mediated by a single central mechanism or by severalinhibit toxicity (Lorenzo et al., 1994; Whitson and Appel,
1995). Ab can also impair mitochondrial redox activity mechanistically distinct pathways.
and increase the generation of free radicals (Shearman
et al., 1994; Behl et al., 1994). Although some reports Animal Models of Neuronal Degeneration
Early animal models of AD attempted to mimic the de-suggested that antioxidants inhibit the toxicity of Ab
and other amyloidogenic peptides (Behl et al., 1994; generation of basal forebrain cholinergic neurons that
occurs in AD because of evidence that this contributesMattson and Goodman, 1995), other laboratories re-
ported no protective effect of the same antioxidants to the amnestic deficit (Davies and Maloney, 1976;
Whitehouse et al., 1982; Bartus et al., 1982). This degen-(Lockhart et al., 1994; Lorenzo et al., 1994). Although
these discrepancies may relate to differences in culture erative process was induced experimentally by fimbria±
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fornix transection in rats. The subsequent degeneration some studies showed that Ab produced neurodegener-
ative changes in the brain (Frautschy et al., 1991; Kowallof basal forebrain cholinergic neurons could be pre-
vented by administration of NGF (Koliatsos et al., 1991; et al., 1991), whereas others reported no effect (Podlisny
et al., 1993). Variability in the degree of Ab aggregationTuszynski et al., 1991). Furthermore, cognitive perfor-
mance was improved in lesioned and normal aged rats appeared to account for these differences (Busciglio et
al., 1992; May et al., 1992). Recent Ab injection studiesby administration of NGF (Dekker et al., 1994; Markow-
ska et al., 1994). These studies raised the possibility have shown that Ab is neurotoxic in vivo when it forms
a fibrillar deposit, an effect that is potentiated by coinjec-that NGF may be therapeutically beneficial in AD. How-
ever, the fimbria±fornix transection system was limited tion of heparin sulfate proteoglycan (Snow et al., 1994;
Giovannelli et al., 1995). Although these animal modelsas a model of AD because it lacked the characteristic
pathological features of the disease. recapitulate varying aspects of AD pathology, there is
currently no animal model that exhibits the entire patho-The development of a transgenic mouse model of
Ab plaque formation became a high priority to test the logical spectrum of the human disease.
hypothesis that Ab deposition can lead to the other
pathological changes associated with AD. This was re- Is Ab Protein the Cause of Dementia in AD?
cently achieved by overexpression of APP containing The hypothesis that Ab deposition is a primary factor
one of the mutations (APP717) associated with familial in the pathogenesis of AD has been challenged on the
AD (Games et al., 1995). These transgenic mice develop basis of studies that show that cortical synapse loss
large numbers of amyloid plaques in the cortex, hippo- and the number of neurofibrillary tangles predict the
campus, and corpus callosum that first appear after 4±6 severity of dementia more accurately than plaque den-
months of age. Importantly, the age dependence and sity (Morris et al., 1991; Terry et al., 1991). Additionally,
neuroanatomical pattern of Ab deposition is similar to synapse loss and up-regulation of endosomal±lyso-
that which occurs in AD, despite expression of the APP somal enzymes can occur early in AD in regions of the
transgene throughout the brain. These results suggest brain that are relatively devoid of plaques (Cataldo et
that region-specific vulnerability of the aging brain may al., 1995). Thus, plaque density is unlikely to be the sole
dictate the pattern of plaque formation. determinant of disease progression. However, since
The brains of APP717 transgenic mice exhibit diffuse plaque formation is a slowly progressive process (Rum-
synaptic and dendritic loss in the cortex. Furthermore, ble et al., 1989), plaque number at any given time may
theamyloid plaques are directlyassociated with reactive not be an accurate indicator of the total Ab burden in
gliosis, dystrophic neurites, and apoptotic cells, sug- the brain. Moreover, Ab fibrils can induce synapse loss
gesting that the plaques induce neurodegenerative and neurodegenerative changes in culture without form-
changes. In earlier studies, transgenic mice that overex- ing plaques (Lorenzo and Yankner, 1994; Howlett et al.,
pressed the APP transgene at much lower levels were 1995), and APP transgenic mice undergo synapse loss
either devoid of pathology (Lamb et al., 1993) or devel- in both plaque-containing and plaque-free regions
oped sparse Ab-immunoreactive deposits and an age- (Games et al., 1995), suggesting that Ab- or APP-related
dependent deficit in spatial learning (Quon et al., 1991; pathology may not be limited to plaques.
Higgins et al., 1994; Moran et al., 1995). Another APP Substantial numbers of amyloid plaques occasionally
transgenic mouse exhibited an age-related behavioral appear in the brain in nondemented individuals, sug-
disorder in the absence of Ab deposition (Hsiao et al., gesting that Ab deposition does not invariably lead to
1995). Although the plaque-forming APP717 transgenic AD (Katzman et al., 1988; Dickson et al., 1991). This may
mouse represents an important advance in developing in part be due to differences in the protein composition
an animal model of AD, a significant limitation is the and structure of plaques in demented and nondemented
lack of neurofibrillary tangle formation (Games et al., individuals (Arai et al., 1990; Mesulam and Geula, 1994).
1995). This may reflect species-specific factors in the However, recent findings suggest that disease modi-
neuronal response to injury, since aged sheep are the fying genes, such as ApoE, may play an important role in
only nonhuman species in which spontaneous neurofi- determining individual vulnerability to neurotoxic insults
brillary tangle formation has been observed (Nelson et such as Ab, affecting the age of onset and rate of pro-
al., 1994). The causal relationship of amyloid deposition gression of clinical symptoms. It is also possible that
to neurofibrillary tangle formation is an unresolved issue Ab by itself may not be sufficient to cause AD, but rather
in AD research (Goedert, 1993; Shin et al., 1993). How- may act to potentiate other age-related pathological
ever, since some families with mutations in APP develop
factors, such as oxidative stress (Lockhart et al., 1994).
the full spectrum of AD neuropathology, the deposition
of amyloid must be related to neurofibrillary tangle for-
ApoEmation at some level.
ApoE is the first known susceptibility gene for the com-Some of the early events surrounding Ab accumula-
mon late-onset form of AD. There are three major allelestion in vivohave been examined inaged rhesus monkeys
of ApoE on chromosome 19ÐE2, E3, and E4. ApoE3 isthat develop senile plaques. Intraneuronal accumulation
the most prevalent allele. A disproportionate increaseof Ab immunoreactivity was observed in association
in the frequency of the ApoE4 allele in patients with late-with neuritic and synaptic degenerative changes, sug-
onset AD was first described by Strittmatter et al. (1993a)gesting that Ab deposition may be a normal concomitant
and has been confirmed by many subsequent studies.of age-related neuronal degeneration (Martin et al.,
The presence of an ApoE2 allele was found to have the1994). The direct effects of Ab in vivo have been exam-
ined by microinjection of Ab in the adult rat brain. Initially, opposite effect, decreasing the risk of AD and delaying
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Figure 3. Potential Pathogenic Mechanisms
Involving ApoE
Individuals carrying the E4 allele of ApoE are
at increased risk of developing AD. The E3
and E4 alleles maydifferentially affect Ab fibril
formation, tau phosphorylation, or choles-
terol transport involved in neurite outgrowth
and synaptogenesis.
disease onset (Corder et al., 1994; Royston et al., 1994). of Ab fibril formation, potentially accelerating the rate
of onset of AD (Figure 3).ApoE is a component of the very low density lipoprotein
(VLDL) and high density lipoprotein (HDL) complexes An alternative pathogenic mechanism for the role of
ApoE in AD has been proposed based on the observa-that mediate the cellular uptake and metabolism of cho-
lesterol (Mahley, 1988). ApoE has been shown to play tion that ApoE binds to the microtubule-associated pro-
tein tau in vitro (Strittmatter et al., 1994). ApoE bindsan important role in the regulation of lipid metabolism
following axonal injury in the peripheral and central ner- only to nonphosphorylated tau, and ApoE3 binds with
significantly higher affinity than ApoE4. It was proposedvous system (Ignatius et al., 1986; Poirier et al., 1991).
Following nerve injury, myelin degeneration induces that ApoE3 may normally act to protect tau from hyper-
phosphorylation in the aging brain. Hyperphosphoryla-ApoE secretion from astrocytes in order to scavenge
and sequester cholesterol. Neuronal uptake of the tion of tau can result in the loss of its ability to bind to
microtubules, possibly leading to cytoskeletal disrup-ApoE±lipoprotein complex is followed by the intracellu-
lar release of free cholesterol that can presumably be tion and the formation of neurofibrillary tangles (Biernat
et al., 1993; Bramblett et al., 1993; Lu and Wood, 1993;transported to nerve terminals where it is utilized for
neurite outgrowth and synaptogenesis. In primary neu- Alonso et al., 1994). According to this model, individuals
with an ApoE4 genotype would be at increased risk forronal cultures, ApoE3 complexed with VLDL increases
neurite outgrowth, whereas the complex containing AD because of decreased levels of the ApoE3 allele that
inhibits tau phosphorylation (Figure 3). ApoE has beenApoE4 is inhibitory (Nathan et al., 1994). It has been
proposed that aged individuals with the ApoE4 allele localized to the neuronal cytoplasm (Han et al., 1994)
and is associated with neurofibrillary tangles in ADmay have accelerated loss of neuronal function because
of a decreased capacity for compensatory neurite out- (Namba et al., 1991; Rebeck et al., 1993). However, a
physiological interaction of ApoE with tau in normal neu-growth and synaptogenesis (Poirier, 1994) (Figure 3).
The only known alteration in the neuropathology of rons has not yet been demonstrated.
AD patients with an ApoE4 allele is a significant increase
in the number of amyloid plaques (Schmechel et al., Newly Identified Transmembrane Proteins
that Confer Susceptibility to AD1993; Rebeck et al., 1993). Furthermore, some individu-
als who are not demented and carry an ApoE4 allele The most common genetic locus for the early-onset
familial form of AD is linked to chromosome 14 (Schel-exhibit increased amyloid plaque formation, suggesting
that ApoE4 may promote Ab deposition independent of lenberg et al., 1992; St George-Hyslop et al., 1992), and
has recently been identified as a new gene designatedother features of AD (Polvikoski et al., 1995). ApoE binds
to soluble Ab in vitro (Strittmatter et al., 1993b) and S182 (Sherrington et al., 1995). S182 is a 467 amino
acid protein with the predicted structure of an integralpromotes amyloid fibril formation in an isoform-specific
manner, with ApoE4 promoting Ab fibrillogenesis more membrane protein containing seven to nine transmem-
brane domains. Five different missense mutations inpotently than ApoE3 (Ma et al., 1994; Sanan et al., 1994;
Wisniewski et al., 1994). These in vitro results are consis- S182 were originally found in families with an aggressive
form of early-onset AD (Figure 1). The mutations weretent with immunohistochemical and biochemical studies
whichdemonstrate that ApoE isassociated with amyloid absent in a large cohort of asymptomatic family mem-
bers and neurologically normal individuals and occurredplaques (Namba et al., 1991; Wisniewski and Frangione,
1992; Rebeck et al., 1993; NaÈslund et al., 1995). Thus, in residues that are highly conserved in the human and
mouse S182 genes, suggesting that the mutations areisoform-specific differences in ApoE production at an
incipient stage of Ab deposition may increase the rate pathogenic. A second transmembrane protein (STM2),
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which is highly homologous to S182, has been identified pathogenesis. The generation of oxygen free radicals
has been implicated in other neurodegenerative disor-on chromosome 1 as the likely genetic locus of familial
AD in Volga German families (Levy-Lahad et al., 1995; ders such as Parkinson's disease and amyotrophic lat-
eral sclerosis (Coyle and Puttfarcken, 1993; Brown,Rogaev et al., 1995; Li et al., 1995). A missense mutation
in this gene cosegregates with AD in seven families. 1995). Evidence of increased oxidative stress in the AD
brain has come from studies showing increased lipidMore than 25 different inherited mutations have now
been identified in S182 and STM2, which have been peroxidation (Subbarao et al., 1990), increased carbonyl
modification of proteins (Smith et al., 1991), and in-named ªpresenilinsº in anticipation of a gene family that
causes early-onset AD (Alzheimer's Disease Collabora- creased oxidation of mitochondrial DNA (Mecocci et al.,
1994). Other studies have shown that there are multipletive Group, 1995; Wasco et al., 1995). Most of the muta-
tions are localized within, or proximal to, a predicted mitochondrial enzyme deficiencies in the AD brain and
decreased cortical glucose metabolism early in the dis-transmembrane boundary, raising the possibility that
they disrupt membrane anchorage or oligomeric protein ease, suggesting impaired energy metabolism (Blass,
1993). There is also evidence that oxidative stress mayinteractions.
The biological functions of the presenilins are un- contribute to the formation of amyloid plaques and neu-
rofibrillary tangles. Inhibition of energy metabolism in-known. S182 and STM2 show significant sequence ho-
mology to two integral membrane proteins from C. eleg- creases the amyloidogenic pathway of APP processing
(Gabuzda et al., 1994), and oxidation of Ab in vitro in-ans, SEL-12 and SPE-4. SEL-12 was identified as a
protein that facilitates signaling through the Notch/LIN- creases its aggregation (Dyrks et al., 1992). Some of the
Ab in plaques shows advanced glycosylation modifica-12 family of receptors that dictate cell fate during devel-
opment (Levitan and Greenwald, 1995). The high degree tions, a posttranslational modification that is promoted
by oxidation and results in increased Ab aggregationof homology (50%±60% identity) between S182, STM2,
and SEL-12 suggests that the presenilins may also be (Smith et al., 1994; Vitek et al., 1994). Oxidative stress
has been implicated in neurofibrillary tangle formationinvolved in this signaling pathway, either by regulating
signal transduction or by affecting the processing of by the observation that oxidation of tau at residue Cys-
322 is required for paired helical filament formation inligands or receptors. The second homologous protein,
SPE-4, is part of a specialized organelle derived from vitro (Schweers et al., 1995) and by the demonstration
that oxidized proteins are present in neurofibrillary tan-the Golgi that is believed to function by segregating
membrane proteins during spermatogenesis (L'Hernault gles in vivo (Smith et al., 1995). Thus, there is a consider-
able body of evidence suggesting that oxidative stressand Arduengo, 1992). A recent study suggests that S182
and STM2 may be localized to the endoplasmic reticu- may be involved in the neurodegenerative process in AD.
The sources of oxidative stress in the AD brain remainlum and Golgi complex in transfected cells (Kovacs et
al., 1996). If this localization is confirmed in vivo, then to beestablished. One possible source is theAb peptide,
which under some conditions can acquire a free radicalit would raise the possibility that presenilins affect the
transport or processing of proteins in thesecretory path- state in vitro (Hensley et al., 1994). This ªradicalizationº
of the Ab peptide has been hypothesized to mediate Abway, potentially affecting the processing of APP and the
production of Ab. This hypothesis is consistent with the toxicity. However, both toxic Ab and nontoxic control
peptides were found to undergo radical formation inobservation that skin fibroblasts from individuals with
S182 mutations produce increased levels of Ab with solution. Another potential source of oxidative damage
in the AD brain is an inflammatory response triggered byan increased proportion of the highly amyloidogenic 42
amino acid form (Scheuner et al., 1995, Soc. Neurosci., microglial activation. Activated microglia that express
complement receptors and major histocompatibility an-abstract).
Perhaps the most intriguing link between the preseni- tigens are closely associated with amyloid plaques
(McGeer et al., 1994). In cell culture, Ab acts synergisti-lins and the disease mechanism in AD is the recent
isolation of a partial cDNA for STM2 using a ªdeath trapº cally with interferon-g to activate microglia, resulting in
the production of neurotoxic nitrogen free radicalsassay (Vito et al., 1996). To isolate genes involved in
apoptosis, apoptosis was induced in a T cell hybridoma (Meda et al., 1995). Ab can also activate the complement
cytolytic pathway in vitro (Rogers et al., 1992). Two pre-after transfection with a cDNA library. Two cDNA clones
liminary clinical studies suggested that anti-inflamma-were selected that modulated apoptosis. One encoded
tory drugs decrease the rate of cognitive decline in AD,a calcium-binding protein that was required for apoptosis
increasing interest in thepotential involvement of inflam-to occur. The other, which encoded the C-terminal 103
matory mechanisms in disease progression (Breitner etamino acids of the murine presenilin STM2, prevented
al., 1992; Rogers et al., 1993).T cell receptor± and FAS-induced apoptosis. However,
Several recent studies suggest that oxidative stressit remains to be determined whether the activity of the
may be an important cause of neuronal apoptosis (Kanetruncated STM2 construct reflects the normal function
et al., 1993; Greenlund et al., 1995). This mechanismof the native protein. Nevertheless, these findings raise
may be involved in the development of AD in individualsthe possibility that presenilins may directly or indirectly
with Down's syndrome (Mann and Esiri, 1989). Corticalregulate cell death pathways.
neurons from the Down's syndrome brain have been
shown to generate significantly increased levels of reac-
Oxidative Stress tive oxygen species leading to apoptotic cell death in
The age dependence of AD has long given rise to specu- culture (Busciglio and Yankner, 1995). The relative con-
tribution of apoptosis to neuronal degeneration in AD islation that oxidative stress may play a role in disease
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tau to microtubules: distinction between PHF-like immunoreactivityunresolved. Although degenerating neurons with DNA
and microtubule binding. Neuron 11, 153±163.fragmentation have been detected in the AD brain by
Blass, J.P. (1993). Pathophysiology of the Alzheimer syndrome. Neu-TUNEL staining, only a subpopulation of the labeled
rology 43, 525±538.nuclei show the classic morphological changes of
Bramblett, G.T., Goedert, M., Jakes, R., Merrick, S.E., Trojanowski,apoptosis (Su et al., 1994; Lassmann et al., 1995). These
J.Q., and Lee, V.M.-Y. (1993). Abnormal tau phosphorylation at Ser396studies suggest that apoptosis, as classically defined,
in Alzheimer's disease recapitulates development and contributesmay not be the only mechanism of neuronal degenera- to reduced microtubule binding. Neuron 10, 1089±1099.
tion in the AD brain. Nevertheless, it is possible that cell
Breen, K.C., Bruce,M., and Anderton, B.H. (1991). b-Amyloid precur-
death in AD may be induced through a final common sor protein mediates neuronal cell±cell and cell±surface adhesion.
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